Core Viewpoint - The company has observed unusual fluctuations in its share price and trading volume, but the board is unaware of any reasons for these changes or any information that needs to be disclosed to prevent a false market [1] Group 1: Share Price and Trading Volume - The board confirmed that it does not know the reasons behind the recent abnormal changes in share price and trading volume [1] - The company has not identified any information that must be disclosed under the relevant regulations to avoid misleading the market [1] Group 2: Business Operations and Financial Status - The board stated that the company's business operations remain normal, and there have been no significant changes in its business and financial status as of the date of the announcement [1] Group 3: Share Buyback Program - The company plans to repurchase shares up to a total of HKD 100 million based on market conditions and funding arrangements [1] - As of November 6, 2025, the company has repurchased a total of 400,000 shares at an approximate total cost of HKD 3,235,320, with an average repurchase price of HKD 8.0883 per share [1] - The board believes that the current share price is below its true value and does not adequately reflect the company's business prospects, indicating confidence in long-term growth and market performance [1]
药师帮股价异动 将回购总额最多1亿港元的股份